Introduction
First, concerns about China leveraging medicine supply chains reflect broader geopolitical risks, especially after disruption during COVID-19 exposed vulnerabilities in global production networks.
Understanding Supply Chain Structure
To begin with, drug production involves multiple stages, including raw materials, intermediates, active ingredients, and final dosage manufacturing across different countries.
Moreover, dependence varies significantly across these stages, making simplistic narratives about reliance on one country misleading and potentially harmful for policymaking.
China’s Real Leverage
On the one hand, China’s dominance is strongest in upstream inputs, such as key starting materials, solvents, and reagents essential for drug synthesis.
On the other hand, its role in active pharmaceutical ingredients varies widely, with overall exposure closer to one quarter of U.S. drug volume.
Additionally, China increasingly expands into downstream production, strengthening its strategic position across the entire pharmaceutical chain.
Hidden Vulnerabilities
Importantly, upstream dependencies are often underestimated because data visibility is limited and many analyses ignore critical chemical processes and shared production nodes.
Furthermore, reliance on dangerous or complex chemical synthesis steps has shifted to China over time, reinforcing structural dependence.
When Supply Chains Become Weapons
Consequently, concentrated control over key inputs creates potential geopolitical leverage, enabling disruptions that could affect a wide range of medicines.
However, historically, drug shortages have mostly resulted from manufacturing issues rather than export restrictions, although future conflicts could change this pattern.
Limits of Current Policy Approaches
Meanwhile, policies focusing only on domestic production of final ingredients fail to address deeper vulnerabilities rooted in upstream dependencies.
Similarly, onshoring without securing access to raw materials provides limited protection against supply disruptions linked to China.
Strategic Recommendations
Therefore, effective responses require a comprehensive approach addressing all production stages, especially upstream chemicals and intermediates.
In addition, collaboration with allies and targeted industrial policies are necessary to reduce risk without wasting limited resources.
Conclusion
Finally, medicine supply chains reveal how economic interdependence can create strategic vulnerabilities, demanding nuanced policies that strengthen resilience rather than relying on incomplete assumptions.
Source:
Wosińska, M. E., & Shi, Y. (2026, March 19). US drug supply chain exposure to China: Myths, omissions, and related insights. Brookings Institution. https://www.brookings.edu/articles/when-medicine-supply-chains-become-weapons-chinas-leverage-and-how-the-u-s-should-respond/